Dr. Jennifer Wang recently joined JW Therapeutics as Head of QC and Analytical Development. Her prior experience and responsibilities includes Associate Director at Abbive Stemcentrx, for CMC control strategy development, method validation and tech transfer for antibody drug conjugates (ADC) cancer therapy. Jennifer also held various positions with increasing responsibilities at Genentech/Roche for 9 years, from Scientist to Sr. Scientist/Sr. Group Leader in Protein Analytical Chemistry and IMP QA. Prior to joining Genentech, Jennifer worked in Analytical Development/QC, Process Development and Formulation at Tanox for 10 years. Jennifer has over 20 years of CMC and Quality experience in biopharmaceutical industry. While at Genentech, she acted as the analytical lead working closely with the Chinese health authorities including NIFDC, CDE, and ChP on assay training, transfer, and validation for 2015 ChP chapters.
Jennifer obtained her PhD degree in Chemical Engineering from Texas A&M University in the US; MS degree in Chemical Engineering, and BS degree in Chemistry from Tsinghua University in Beijing, China.